Antisense Therapeutics Selected to Present at Biotech Showcase™ 2014 PR Newswire SAN FRANCISCO, Jan. 7, 2014 SAN FRANCISCO, Jan. 7, 2014 /PRNewswire/ -- Antisense Therapeutics Limited ("ANP" or...
Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial PR Newswire TOORAK, Australia, Dec. 23, 2013 TOORAK, Australia, Dec. 23, 2013 /PRNewswire/ -- Antisense Therapeutics...
ANP to present at and attend major US investment, partnering and industry conferences PR Newswire TOORAK, Australia, Aug. 28, 2013 TOORAK, Australia, Aug. 28, 2013 /PRNewswire/ -- Antisense...
Antisense Therapeutics Announces Launch of Level 1 American Depository Receipt Program Phase 2a Clinical Study for MS and Proof of Concept Study for Psoriasis Currently Underway MELBOURNE...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0.75 | 0.75 | 0.75 | 0 | 0 | DR |
26 | 0 | 0 | 0.75 | 0.75 | 0.75 | 0 | 0 | DR |
52 | 0 | 0 | 0.75 | 0.75 | 0.75 | 0 | 0 | DR |
156 | 0 | 0 | 0.75 | 0.75 | 0.75 | 0 | 0 | DR |
260 | 0 | 0 | 0.75 | 0.75 | 0.75 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.